Adipose-Derived Stem & Regenerative Cells Improve Fat Graft Retention
in Preclinical Study
Dec 15 2007, 6:55 AM EST
News source: Business Wire
Cytori Therapeutics, Inc. (NASDAQ:CYTX) reported positive preclinical
results demonstrating adipose-derived stem and regenerative cells
improved the quality and long-term retention of a fat graft,
representing a potential new approach in reconstructive surgery. The
benefit of adipose-derived stem and regenerative cells was observed
at six months and was retained through the end of the study at nine
months. Results were presented at the 30th annual San Antonio Breast
Cancer Symposium. (Poster #4072)
"Fat tissue transfers enhanced with adipose tissue-derived stem and
regenerative cells can provide a novel option for reconstructive
surgery," said Marc H. Hedrick, M.D., president of Cytori
Therapeutics. "Using Cytori's Celution(TM) System to provide stem and
regenerative cells would simplify, standardize and improve the
predictability of shape and volume outcomes for fat transfer
procedures, including breast reconstruction following partial
mastectomy."
In the preclinical rodent study, donor adipose-derived stem and
regenerative cells, or saline, was combined with donor adipose tissue
and then transplanted onto recipient skulls. After six and nine
months, grafts were harvested and weighed. The mean weight of cell-
enhanced grafts at six and nine months was two times greater than
grafts with saline (p = 0.019 at six months; p=0.034 at nine months).
Histological analysis revealed the cell-enhanced grafts contained
less fibrous tissue, suggesting improved graft quality. Additionally,
donor stem and regenerative cells were present within grafted adipose
tissue and were incorporated into blood vessel walls within the fat
graft.
A related preclinical study further established safety of adipose-
derived stem and regenerative cells by demonstrating these cells had
no effect on the promotion of tumor growth. Human fat grafts with or
without adipose-derived stem and regenerative cells were transplanted
onto mammary fad pads of rodent recipients injected with human breast
cancer cells. The study was repeated with three human fat donors.
After eight weeks, the study found no evidence that enhancing the fat
graft of any of the donors with stem and regenerative cells had any
effect on the in vivo growth rate, volume, or metastasis of the human
breast tumors.
Cytori Therapeutics
Cytori Therapeutics' (NASDAQ: CYTX) goal is to be the global leader
in regenerative medicine. The company is dedicated to providing
patients with new options for reconstructive surgery, developing
treatments for cardiovascular disease, and banking patients' adult
stem and regenerative cells. To reach its goal, Cytori is developing
its innovative Celution(TM) System to separate and concentrate a
patient's own adult stem and regenerative cells from adipose (fat)
tissue for these cells to be delivered back to the patient during the
same surgical procedure. The Celution(TM) System will be introduced
in 2008 in Europe for reconstructive surgery and launched in Japan
for cryopreserving a patient's own stem and regenerative cells.
Clinical trials are ongoing or planned in cardiovascular disease,
spinal disc degeneration, gastrointestinal disorders, and other unmet
medical needs. www.cytoritx.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding
events, trends and prospects of our business, which may affect our
future operating results and financial position. Such statements are
subject to risks and uncertainties that could cause our actual
results and financial position to differ materially. Some of these
risks and uncertainties include our history of operating losses, the
need for further financing, regulatory uncertainties, dependence on
performance of third parties, and other risks and uncertainties
described (under the heading "Risk Factors") in Cytori Therapeutics'
Form 10-K annual report for the year ended December 31, 2006. We
assume no responsibility to update or revise any forward-looking
statements to reflect events, trends or circumstances after the date
they are made.
http://www.genengne
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Fed Cuts Rates Again - Think you pay you much for your mortgage? No SSN Required - Estimate New Payment.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment